DOCSLIB.ORG

Lower Extremity Major and Minor Amputations in the High Risk Patient

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lower Extremity Major and Minor Amputations in the High Risk Patient THE DIABETIC FOOT Lower Extremity Major and Minor Amputations in the 57 High Risk Patient These procedures come with high morbidity and mortality rates. BY KIRSTI A. DIEHL, DPM, LATRICIA ALLEN, DPM, MPH, MICHAEL FRENCH, JD, AND VICKIE R. DRIVER, DPM artial lower limb ampu- ripheral arterial disease (PAD). The healing. For example, patients with tation is a common out- literature recognizes that approxi- ischemic wounds may require revas- come in the high risk pa- mately 80%-85% of non-traumatic cularization to restore proper blood tient with lower extremity chronic ulcerations, isch- Pemia, and infection. The significant Factors leading to the chronicity of a wound decline in the quality of life and eco- nomic burden caused by lower ex- are variable and must be constantly evaluated and tremity infections leading to ampu- tations in the high risk population treated to promote wound healing. warrants further study in order to better understand the elements that improve limb viability and the caus- amputations are preceded by lower flow to heal. al factors related to major limb loss extremity ulcers.2,3 Diabetic neuropathic ulcers re- (below or above the knee).1 Complications of non-heal- sulting from increased pressure due The unfortunate pathway to am- ing wounds increase the longer the to osseous deformities may require putation in the high risk patient with wound is present. Factors leading to a variety of podiatric surgical inter- a lower limb ulceration or infection the chronicity of a wound are vari- ventions, conservative methods to can be caused by major and minor able and must be constantly evalu- offload the area, such as total contact etiologies, mainly diabetes and pe- ated and treated to promote wound © Stuart Miles | Dreamstime.com Continued on page 58 www.podiatrym.com NOVEMBER/DECEMBER 2015 | PODIATRY MANAGEMENT THE DIABETIC FOOT Amputations (from page 57) tremity amputations. Approximate- It has been estimated by the ly 185,000 lower limb amputations United States government that ap- casting, or advanced wound healing occur in the United States of America proximately two out of every five therapies. Of note, only three prod- annually, with the majority (54%) Americans will develop type 2 diabe- ucts are approved by the Food and performed to treat peripheral arterial tes at some point during their adult Drug Administration (FDA) to treat disease (PAD) with or without diabe- lives.10 These statistics correspond diabetic foot ulcers (Figure 1). tes.6,7 Diabetes has recently reached with high expense, with costs in the pandemic status with approximately United States reported in 2014 to be Topical Wound Healing Agents 387 million people worldwide suffer- around $612 billion (see Figure 2).9 Apligraf and Dermagraft are both ing from the disease and 4.9 million Chronic diabetes causes peripheral bio-engineered skin substitutes (by deaths in 2014 caused directly by di- arterial disease (PAD) and sensory Organogenesis) and Becaplermin (Re- abetes.8,9 It is estimated that in the neuropathy, a combination that leads granex) is a recombinant platelet-de- United States, 29.1 million people (or to ulcers, diabetic foot infections, and rived growth factor (PDGF) applied 9.3% of population) have diabetes, often the need for lower extremity topically as a gel.4,5 The forecast for with 21 million being diagnosed and amputation.11 other diabetic foot ulcer treatments 8.1 million being undiagnosed.10 Continued on page 61 is promising, with multiple products currently in clinical trial (Figure 1). Topical wound healing agents likely to be available within the next FIGURE 1: five years include: Aclerastide by Derma Sciences (angiotensin analog Diabetic Foot Ulcer NorLeu3-A1-7 with the active pharma- 4,5 58 ceutical ingredient DSC127), Trafer- Wound Care Products min by Olympus Biotech (recombi- nant human basic fibroblast growth FDA approved: factor engineered using Escherichia coli), and CureXcell® by Macrocure Regranex/Becaplermin Recombinant platelet-derived (activated leukocyte suspension).4,5 (by Smith & Nephew) growth factor (PDGF) The two first topical antibacterials are Pharmacologic wound also likely to be on the market within healing agent the next five years: Locilex™ by Dipex- Apligraf® Cultured cells from neonatal foreskin and ium Pharmaceuticals (Pexiganan ac- (by Organogenesis) bovine type 1 collagen etate cream 1%) and Cogenzia by In- Bioengineered bi-layered nocoll (gentamicin collagen sponge).5 skin substitute In the more distant future, gene encoding growth factors via viral Dermagraft® Human neonatal dermal fibroblasts vectors, cytokine inhibition, topical (by Organogenesis) neuropeptides, and stem cell-based Bioengineered skin substitute therapies may be available.4 Unfor- tunately, the cost of the aforemen- Clinical trials in progress: tioned wound care products (old and new) is high and, without consistent Aclerastide Angiotensin analog NorLeu3-A(1-7), off-loading and debridement, failure (by Derma Sciences) active pharmaceutical ingredient DSC127 of the products is likely, and the risk Wound healing agent for partial limb amputation remains.4 Trafermin Recombinant human basic fibroblast growth Common Complications (by Olympus Biotech) factor engineered using Escherichia coli Common complications affecting Wound healing agent diabetic and ischemic patients are ® chronic and poor healing lower ex- CureXcell Activated leukocyte suspension (by Macrocure) tremity ulcers, soft tissue and bone Wound healing agent infections requiring a plethora of clin- ical outpatient visits, multiple hospital Locilex™ Pexiganan acetate cream 1% admissions for intravenous (IV) an- (by Dipexium Pharmaceuticals) tibiotics, use of expensive adjunctive treatments (i.e., hyperbaric oxygen Cogenzia Gentamicin collagen sponge therapy and negative pressure wound (by Innocoll) therapy), and surgical procedures that often lead to non-traumatic lower ex- NOVEMBER/DECEMBER 2015 | PODIATRY MANAGEMENT www.podiatrym.com THE DIABETIC FOOT FIGURE 2: Diabetes Statistics9,10 n People with DM globally (387 million) n People with DM in U.S.A. (29.1 million) n People undiagnosed globally (179 million) n People undiagnosed in the U.S.A. (8.1 million) Millions n People with prediabetes in U.S.A. (86 million) n Deaths cause by DM globally (4.9 million) 0 50 100 150 200 250 300 350 400 Amputations (from page 58) lesion.20 If a lesion is suspected, it must be localized, usu- ally through conventional angiogram.20 About 50% of patients who have foot amputations Revascularization is then completed if adequate ves- die within five years, which is a worse mortality rate than sels or collateral vessels are seen proximal and distal most cancers.12 It has been reported that 55% of diabetics to the occlusion via open surgery versus endovascular 61 with a lower extremity amputation will require amputa- surgery.20,21 The gold standard is open revascularization, tion of the contralateral leg within two to three years.13 Continued on page 62 Foot ulcers are expensive to treat, with uncomplicated diabetic foot ulcers costing up to $8,000 and infected foot ulcers up to $17,000.14 If amputation is required to resolve the ulcer, the cost skyrockets to $45,000.14 In 1998, a large study obtained the hospital discharge records for all veterans hospitals to examine the epidemiol- ogy of lower extremity disease in veterans with diabetes.15 It was found that only 16% of the population was com- prised of diabetics; however, half of all patients hospital- ized due to lower extremity ulcerations had diabetes.15 A more recent study from 2012 stated that 20% of veterans using the Veterans Health Affairs Hospitals are affected by diabetes (or more than one million veterans at any given time).16 The 1998 study showed that 10,532 hospital dis- charges consisted of diabetics with ulcerations.15 34% of peripheral vascular disease procedures and 64% of ampu- tations were performed on patients with diabetes.15 Vascular Disease as an Etiology 82% of vascular-related lower extremity amputations in the United States are associated with diabetes; however PAD, with or without diabetes, is another leading cause of lower extremity amputation.17-19 PAD is a progressive dis- ease and leads to Critical Limb Ischemia (CLI) in its most advanced form.19 The global prevalence of PAD is overall 3%-10% with an increase to 15%-30% in age groups greater than 70 years old, and is even greater in the dia- betic population.19 Of patients with CLI, 50% will require revascularization and 25% will require amputation.19 Initial work-up for PAD is prompted by risk factors (i.e., smoking history, claudication, diabetes, lower ex- tremity ulceration, etc.).20 Non-invasive vascular studies, using ankle brachial index (ABIs) and pulse volume re- cordings (PVRs), may or may not indicate an occlusive www.podiatrym.com NOVEMBER/DECEMBER 2015 | PODIATRY MANAGEMENT THE DIABETIC FOOT Amputations (from page 61) Unfortunately, within the United puted tomography scan (CT scan)), States, limb preservation teams are possible bone biopsy if osteomyelitis which surpasses endovascular pro- habitually consulted late in the dis- is suspected, debridement, post-de- cedures in terms of durability and re- ease process, after foot infections have bridement wound culture and sen- duced re-occurrence. For this reason, caused significant pathology, which sitivity (with gram stain), and infec- tious disease specialists should be consulted, if necessary.24 Non-invasive vascular studies Vascular surgical procedures, should be completed
Load more

Recommended publications
  • Biomaterials: a Potential Pathway to Healing Chronic Wounds?
    DR. BENJAMIN DAVID ALMQUIST (Orcid ID : 0000-0001-9718-777X) Received Date : 25-Feb-2016 Revised Date : 17-Nov-2016 Accepted Date : 28-Dec-2016 Article type : Viewpoint Biomaterials: A potential pathway to healing chronic wounds? Mara A Pop1 and Benjamin D Almquist1 1. Department of Bioengineering, Imperial College London, London SW7 2AZ, UK Article Corresponding Author: Benjamin D Almquist Email: [email protected] Declarations: None Key Words: biomaterials, chronic wound, wound healing, diabetic ulcer, tissue repair Abstract Chronic dermal wounds are a devastating problem that disproportionally affect individuals with conditions such as diabetes, paralysis, or simply old age. These wounds are extremely challenging to treat due to a heterogeneous combination of causative factors, creating a This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as Accepted doi: 10.1111/exd.13290 This article is protected by copyright. All rights reserved. substantial burden on healthcare systems worldwide. Despite their large impact, there is currently a startling lack of options for effectively treating the underlying biological changes that occur within the wounds. Biomaterials possess an enticing ability to provide new comprehensive approaches to healing these devastating wounds; advanced wound dressings are now being developed that enable the ability to coordinate temporal delivery of multiple therapeutics, protect sensitive biologics from degradation, and provide supportive matrices that encourage the growth of tissue. This positions biomaterials as a potential ‘conductor’ of wound repair, allowing them to simultaneously address numerous barriers to healing, and in turn providing a promising pathway to innovative new technologies for driving successful healing.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Access Tier 4 PPO Prescription Drug List CDI Version
    Pharmacy | PDL | California 2021 California Access Large Group 4-Tier PPO Prescription Drug List Please note: This Prescription Drug List (PDL) is accurate as of September 1, 2021 and is subject to change after this date. All previous versions of this PDL are no longer in effect. Your estimated coverage and copay/coinsurance may vary based on the benefit plan you choose and the effective date of the plan. This PDL can also be accessed online at myuhc.com > Pharmacy Information > Prescription Drug Lists > California plans > Large Group - Access. Plan-specific coverage documents may be accessed online at uhc.com/statedruglists > Large Group Plans > California. If you are a UnitedHealthcare member, please register or log on to myuhc.com, or call the toll-free number on your health plan ID card to find pharmacy information specific to your benefit plan. This PDL is applicable to the following health insurance products offered by UnitedHealthcare: • Navigate • Navigate Plus • Choice • Choice Plus • Select • Select Plus • Core • Core Essential • Options PPO • Non-Differential PPO Updated 7/13/2021 8/21 © 2021 United HealthCare Services, Inc. All Rights Reserved. WF4335930-A Contents At UnitedHealthcare, we want to help you better understand your medication options. ................................................. 3 How do I use my PDL? .................................................. 4 What are tiers? ........................................................ 5 When does the PDL change? ............................................. 5 Utilization Management Programs ......................................... 6 Your Right to Request Access to a Non-formulary Drug ....................... 6 Requesting a Prior Authorization or Step Therapy Exception ................... 7 How do I locate and fill a prescription through a retail network pharmacy? . 7 How do I locate and fill a prescription through the mail order pharmacy? .
    [Show full text]
  • Becaplermin (Regranex) Reference Number: ERX.NPA.31 Effective Date: 07.01.15 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
    Clinical Policy: Becaplermin (Regranex) Reference Number: ERX.NPA.31 Effective Date: 07.01.15 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Becaplermin (Regranex®) is a human platelet-derived growth factor. FDA Approved Indication(s) Regranex is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief, and infection control. Limitation(s) of use: • The efficacy of Regranex gel has not been established for the treatment of pressure ulcers and venous stasis ulcers and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue (Stage I or II, IAET staging classification) or ischemic diabetic ulcers. • The effects of Regranex gel on exposed joints, tendons, ligaments, and bone have not been established in humans. • Regranex gel is a non-sterile, low bioburden preserved product. Therefore, it should not be used in wounds that close by primary intention. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary. It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Regranex is medically necessary when the following criteria are met: I.
    [Show full text]
  • Products Containing Butalbital Intravenous Antibiotics for Treatment of MRSA And
    October 2010, Volume 3, Issue 3 Products Containing Butalbital Intravenous Antibiotics for Treatment of Combination analgesics containing butalbital are MRSA and VRE indicated for the relief of symptomatic tension-type Intravenous (IV) antibiotics – Cubicin, Zyvox, Synercid, headache (TTH). However, the Institute for Clinical Tygacil, Vibativ, and vancomycin are FDA-approved for Systems Improvement (ICSI) does not recommend the the treatment of methicillin-resistant Staphylococcus use of agents containing butalbital for the treatment of aureus (MRSA). Zyvox and Synercid are also FDA- headaches. Instead, acetaminophen, aspirin, and approved for the treatment of vancomycin-resistant NSAIDS are recommended for acute treatment of TTH. enterococci (VRE) infections. However, clinical literature Amitriptyline and venlafaxine may be appropriate for indicates that Cubicin and Tygacil also have activity prophylactic therapy. Additionally, the overuse of against VRE infections. According to the Infectious products containing butalbital has been associated with Diseases Society of America (IDSA) guidelines, cases of rebound headache. Data reported from the vancomycin is the antibiotic of choice for skin and soft American Migraine Prevalence and Prevention study tissue infections caused by MRSA. Vancomycin is also suggests that episodic use of butalbital as infrequently as recommended as the agent of choice for MRSA five days per month may lead to chronic daily headache bacteremia, endocarditis, and osteomyelitis. For patients and medication overuse headache. who fail to respond or cannot tolerate vancomycin, Cubicin, Zyvox, Synercid, and Tygacil are all potential treatment options. Based on a recent utilization review conducted by MassHealth, it has been determined that products MassHealth has reviewed the IV antibiotics with activity containing butalbital will have quantity limits to minimize against MRSA and VRE infections in order to identify the potential overutilization of these agents.
    [Show full text]
  • Becaplermin) Outcome of a Procedure Under Article 20 of Regulation (EC) No 726/2004
    18 February 2010 EMA/312452/2009 EMEA/H/C/212/A20/33 Questions and answers on the review of Regranex (becaplermin) Outcome of a procedure under Article 20 of Regulation (EC) No 726/2004 The European Medicines Agency has completed a review of Regranex at the request of the European Commission, following concerns about a possible risk of cancer in patients using the medicine. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Regranex continue to outweigh its risks, but that it should not be used in patients who have cancers of any type, including skin cancer. In addition, the manufacturer has been asked to conduct more research to investigate the way the medicine is absorbed by the body and its potential risks. What is Regranex? Regranex is a gel that contains the active substance becaplermin. It is used together with other wound care measures to help the healing of long-term neuropathic skin ulcers (ulcers caused by a nerve problem) in people with diabetes. The active substance in Regranex, becaplermin, is a copy of a human protein called platelet-derived growth factor-BB. Growth factors are proteins that stimulate cells to multiply. Becaplermin works in the same way as the naturally produced growth factor by stimulating cell growth and helping the growth of normal tissue for healing. Regranex has been authorised in the European Union (EU) since 29 March 1999 and is marketed in seven Member States1. Why was Regranex reviewed? In January 2009, the CHMP assessed the application for the renewal of the marketing authorisation for Regranex.
    [Show full text]
  • Ibm Micromedex® Carenotes Titles by Category
    IBM MICROMEDEX® CARENOTES TITLES BY CATEGORY DECEMBER 2019 © Copyright IBM Corporation 2019 All company and product names mentioned are used for identification purposes only and may be trademarks of their respective owners. Table of Contents IBM Micromedex® CareNotes Titles by Category Allergy and Immunology ..................................................................................................................2 Ambulatory.......................................................................................................................................3 Bioterrorism ...................................................................................................................................18 Cardiology......................................................................................................................................18 Critical Care ...................................................................................................................................20 Dental Health .................................................................................................................................22 Dermatology ..................................................................................................................................23 Dietetics .........................................................................................................................................24 Endocrinology & Metabolic Disease ..............................................................................................26
    [Show full text]
  • INN Working Document 05.179 Update December 2010
    INN Working Document 05.179 Update December 2010 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 12/2010 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2010 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • REGRANEX® (Becaplermin) Gel
    PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 1/18/2018 SECTION: DRUGS LAST REVIEW DATE: 2/18/2021 LAST CRITERIA REVISION DATE: 2/18/2021 ARCHIVE DATE: REGRANEX® (becaplermin) gel Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Large Group Tier 4 HMO and PPO Prescription Drug List DMHC Version
    Pharmacy | PDL | California 2021 California Advantage Large Group 4-Tier HMO and PPO Prescription Drug List Please note: This Prescription Drug List (PDL) is accurate as of September 1, 2021 and is subject to change after this date. All previous versions of this PDL are no longer in effect. Your estimated coverage and copay/coinsurance may vary based on the benefit plan you choose and the effective date of the plan. This PDL can also be accessed online at myuhc.com > Pharmacy Information > Prescription Drug Lists > California plans > Large Group - Advantage. Plan-specific coverage documents may be accessed online at uhc.com/statedruglists > Large Group Plans > California. If you are a UnitedHealthcare member, please register or log on to myuhc.com, or call the toll-free number on your health plan ID card to find pharmacy information specific to your benefit plan. This PDL is applicable to the following health insurance products offered by UnitedHealthcare: • Navigate • Options PPO • Navigate Plus • Non-Differential PPO • Choice • SignatureValue • Choice Plus • SignatureValue Advantage • Select • SignatureValue Alliance • Select Plus • SignatureValue Focus • Core • SignatureValue Harmony • Core Essential • Doctors Plan Please refer to your ID card for plan type (HMO or PPO). Updated 7/13/2021 7/21 © 2021 United HealthCare Services, Inc. All Rights Reserved. WF4335930-H Contents At UnitedHealthcare, we want to help you better understand your medication options. ..................................................... 3 How do I use my PDL? .................................................. 4 What are tiers? ........................................................ 5 When does the PDL change? ............................................. 5 Utilization Management Programs ......................................... 6 Your Right to Request Access to a Non-formulary Drug ....................... 6 Requesting a Prior Authorization or Step Therapy Exception ..................
    [Show full text]
  • Regranex, INN-Becaplermin
    EMA/163092/2010 EMEA/H/C/212 EPAR summary for the public Regranex becaplermin This document is a summary of the European Public Assessment Report (EPAR)authorised for Regranex. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Regranex. longer What is Regranex? Regranex is a gel that contains the active substanceno becaplermin. What is Regranex used for? Regranex is used together with other wound care measures to help granulation (healing) of long-term skin ulcers in people with diabetes. Regranex is used on neuropathic ulcers up to 5 cm2 in size. Neuropathic ulcers are caused by a nerve problem, and not by a problem with the blood supply to the area affected. product The medicine can only be obtained with a prescription. How is Regranex used? Treatment with Regranex should be started and monitored by a doctor who has experience in the management of diabetic wounds. The ulcerMedicinal should be cleaned with water or saline (salt) solution before each application of Regranex. The gel should then be applied as a layer to the entire surface of the ulcers once a day using a clean application aid, such as a cotton swab. The sites should then be covered by a moist saline gauze dressing to keep the area moist while the ulcers are healing. The dressing should not be air- or watertight. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2010.
    [Show full text]